Modality
Degrader
MOA
VEGFi
Target
TNFα
Pathway
Tau
NarcolepsyGastric Ca
Development Pipeline
Preclinical
~Jun 2016
→ ~Sep 2017
Phase 1
~Dec 2017
→ ~Mar 2019
Phase 2
Jun 2019
Phase 2Current
NCT07777522
2,143 pts·Gastric Ca
2019-06→TBD·Not yet recruiting
2,143 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
P2/3
Not yet…
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07777522 | Phase 2/3 | Gastric Ca | Not yet recr... | 2143 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| VRT-6833 | Vertex Pharma | Preclinical | ALK | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| Sovanaritide | Argenx | Phase 3 | TNFα | |
| BGN-8936 | BeiGene | Phase 1/2 | FXIa | |
| Capifutibatinib | Intra-Cellular | Phase 3 | GIP-R |